Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$5.85 ▼ -0.04
(-0.68%)
MKT CAP: $361.8M • VOL: 854.7K
52W L $5 52W H $14
ROARABLE / RQD
D- • 42/100
PIOTROSKI
3 / 9
KYTX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$169.8M | -$142.6M | -$62.4M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$161.3M | -$127.5M | -$60.4M |
| EBITDA (Normalized) | -$169.8M | -$140.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$153.7M | -$114.3M | -$52.4M |
| Capital Expenditures (CapEx) | $5.0K | $2.2M | — |
| Free Cash Flow (FCF) | -$153.7M | -$116.5M | -$52.4M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $124.1M | $96.6M | — |
| Total Debt (Short + Long Term) | $24.7M | — | — |
| Total Stockholders' Equity | $232.3M | $266.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR KYTX.